Publication:
Uric acid in metabolic syndrome: from an innocent bystander to a central player

dc.contributor.coauthorJensen, Thomas
dc.contributor.coauthorSolak, Yalçın
dc.contributor.coauthorLe, Myphuong
dc.contributor.coauthorRoncal-Jimenez, Carlos
dc.contributor.coauthorRivard, Chris
dc.contributor.coauthorLanaspa, Miguel A.
dc.contributor.coauthorNakagawa, Takahiko
dc.contributor.coauthorJohnson, Richard J.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAcar, Ömer
dc.contributor.kuauthorEsen, Tarık
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorKiremit, Murat Can
dc.contributor.kuauthorSağ, Alan Alper
dc.contributor.kuauthorTarım, Kayhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:12:20Z
dc.date.issued2016
dc.description.abstractUric acid, once viewed as an inert metabolic end-product of purinemetabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non- alcoholic fatty liver disease, and chronic kidney disease. Several experimental and clinical studies support a role for uric acid as a contributory causal factor in these conditions. Here we discuss some of the major mechanisms linking uric acid to metabolic and cardiovascular diseases. At this time the key to understanding the importance of uric acid in these diseases will be the conduct of large clinical trials in which the effect of lowering uric acid on hard clinical outcomes is assessed. Elevated uric acid may turn out to be one of the more important remediable risk factors for metabolic and cardiovascular diseases.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipNIDDK NIH HHS [K01 DK095930, R03 DK105041] Funding Source: Medline
dc.description.volume29
dc.identifier.doi10.1016/j.ejim.2015.11.026
dc.identifier.eissn1879-0828
dc.identifier.issn0953-6205
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-84950282194
dc.identifier.urihttps://doi.org/10.1016/j.ejim.2015.11.026
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9785
dc.identifier.wos373718800013
dc.keywordsUric acid
dc.keywordsMetabolic syndrome
dc.keywordsHypertension
dc.keywordsDiabetes mellitus
dc.keywordsKidney disease
dc.keywordsCardiovascular disease
dc.keywordsFatty liver-disease
dc.keywordsGlucose-sweetened beverages
dc.keywordsMuscle-cell-proliferation
dc.keywordsChronic kidney-disease
dc.keywordsBlood-pressure
dc.keywordsOxidative stress
dc.keywordsCardiovascular-disease
dc.keywordsEndothelial dysfunction
dc.keywordsNitric-oxide
dc.keywordsRisk-factors
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Internal Medicine
dc.subjectMedicine
dc.subjectGeneral and internal medicine
dc.titleUric acid in metabolic syndrome: from an innocent bystander to a central player
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorKiremit, Murat Can
local.contributor.kuauthorAcar, Ömer
local.contributor.kuauthorEsen, Tarık
local.contributor.kuauthorSağ, Alan Alper
local.contributor.kuauthorTarım, Kayhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files